WO2001013882A1 - Methods of lightening keratinous tissue by topical application of oxime compound containing compositions - Google Patents
Methods of lightening keratinous tissue by topical application of oxime compound containing compositions Download PDFInfo
- Publication number
- WO2001013882A1 WO2001013882A1 PCT/US2000/018731 US0018731W WO0113882A1 WO 2001013882 A1 WO2001013882 A1 WO 2001013882A1 US 0018731 W US0018731 W US 0018731W WO 0113882 A1 WO0113882 A1 WO 0113882A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wherem
- alkyl
- ethanedione
- furyl
- group
- Prior art date
Links
- 0 *CCCC(CC=*)C(C(*)=NO)=* Chemical compound *CCCC(CC=*)C(C(*)=NO)=* 0.000 description 2
- NQENBSZUCQDNRW-UHFFFAOYSA-N C=C(C(c1ccc[s]1)=C)c1ccc[s]1 Chemical compound C=C(C(c1ccc[s]1)=C)c1ccc[s]1 NQENBSZUCQDNRW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/08—Preparations for bleaching the hair
Definitions
- the subject invention relates to the field of lightening keratinous tissue, particularly rnarnmalian keratinous tissue, by application of compositions to the keratinous tissue, e.g , skin
- the invention further relates to methods of lightemng keratmous tissue which mvolve the topical application of compositions containing oxime compounds.
- the present invention relates to methods of hghtenmg hyperpigmented regions m sk n by topical application of such compositions
- Extrinsic factors include ultraviolet radiation (e g , from sun exposure), heat, wind, low humidity, harsh surfactants, abrasives, and the like.
- Intrinsic factors include chronological agmg and other biochemical changes from within the skin Whether extrinsic or intrinsic, these factors result in visible and/or tactile signs of skin agmg, such as wrinkling, saggmg, inelasticity, sallowness, changes in skin pigmentation and other histological changes associated with skin agmg.
- extrinsic or intrinsic factors may result in regions of hyperpigmentation m the skin.
- Certain forms of non-uniform pigmentation or hyperpigmentation e.g., age spots, freckles, pigment spots, brown spots, liver spots, melasma, cholasma, ephehdes, semle lentigenes, suntan, melanoderma, hyperpigmented macules, sun spots, melanin spots, brown patches, pigment blotchmess, mottled pigmentation, inflammatory and post-inflammatory hyperpigmentation (e.g., from acne, abrasion, ingrown hairs, insect bites, etc.), pregnancy spots, moles, and the like involving concentration of melanin m the skin, are believed to result from changes in the melanocytes and the keratmocytes present m the epidermis Melanocytes, which are located at the base of the epidermis,
- Tyrosinase catalyzes the hydroxylation of tyrosine and the oxidation of DOPA to DOPA quinone:
- compositions contammg oxime compounds are useful for lightemng keratmous tissue, including nails, hair, and skin (especially hyperpigmented regions of skin).
- the present mvention relates to methods of lightemng keratmous tissue which comprise topically applymg to the keratmous tissue m need of such treatment a safe and effective amount of a composition comprising a safe and effective amount of an oxime compound and a dermatologically acceptable earner for the oxime compound More particularly, the present mvention relates to methods of lightemng skin, e g , lightemng hyperpigmented regions of skin, and of lightemng skin by regulating melanin m skin, m the same manner as mentioned above
- compositions which contam certam oxime compounds are useful for achieving lightemng of keratmous tissue, mcludmg lightemng of hyperpigmented regions in mammalian skm and lightemng of hair and nail beds when applied topically to the respective keratmous tissue types.
- the subject mvention is not limited to any particular mechamsm of action, but is believed to operate by the inhibition of oxidative processes mvolved in the non-enzymatic steps m melanin production and/or by preventing reactive oxygen/oxygen radical stimulation (oxidative stress) of melanocytes which results m initiation of the melanin production pathway within the melanocytes, e g , which can occur with UV or sunlight exposure or other intrinsic or extrinsic stress, such as that mduced by mflammation, on the melanocyte.
- oxidative stress reactive oxygen/oxygen radical stimulation
- compositions of the present mvention can comprise, consist essentially of, or consist of, the essential as well as optional ingredients and components described herem
- consisting essentially of means that the composition or component may mclude additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
- keratmous tissue refers to keratin-containing layers disposed as the outermost protective covering of mammals which mcludes, but is not limited to, skin, hair, and nails (e.g., toenails, fingernails, hooves, cuticles, etc.).
- topical application means to apply or spread the compositions of the present mvention onto the surface of the keratmous tissue
- preferred compositions of the present mvention are those m a form mtended to be left m contact with the keratmous tissue for an extended pe ⁇ od (e.g., for several hours) after topical application, e.g., typical usage of a cream, lotion, moisturizer or the like.
- compositions or components thereof so described are suitable for use m contact with mammalian keratmous tissue, e.g , that of humans, without undue toxicity, incompatibility, instability, allergic response, and the like.
- safe and effective amount means an amount of a compound or composition sufficient to significantly mduce the mtended benefit, but low enough to avoid se ⁇ ous side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan
- hyperpigmentation means refers to concentrations of melanin m the skm which result m age spots, freckles, pigment spots, brown spots, liver spots, melasma, cholasma, ephehdes, semle lentigenes, suntan, melanoderma, hyperpigmented macules, sun spots, melanin spots, brown patches, pigment blotchiness, mottled pigmentation, inflammatory and post-inflammatory hyperpigmentation (e g , from acne, abrasion, ingrown hairs, insect bites, etc ), pregnancy spots, moles, and the like which are believed to result from changes m the melanocytes and the keratmocytes present m the epidermis.
- hyperpigmentation means refers to concentrations of melanin m the skm which result m age spots, freckles, pigment spots, brown spots, liver spots, melasma, cholasma, ephehdes, semle lent
- compositions of the present mvention are especially useful for regulating keratmous tissue pigmentation associated with melanin.
- regulatmg keratmous tissue pigmentation m cludes skm lightemng Skm lightening involves diminishing, mmiimzmg and/or effacing existing melamn m skm (therapeutic), and/or delaying, minimizing and/or preventmg the formation of melamn in skm (prophylactic), including hyperpigmented regions of skm.
- compositions of the present mvention comprise a safe and effective amount of an oxime compound.
- the oxime compound may have the following structure
- -Rl is aryl, it is preferably selected from substituted and unsubstituted, preferably unsubstituted, 2-furyl, 3-furyl, 2-th ⁇ enyl, 3-th ⁇ enyl, 2-pyrrolyl, 3- ⁇ yrrolyl and phenyl, more preferably from 2-furyl, 2-th ⁇ enyl, 2-pyrrolyl and phenyl; more preferably 2-furyl, and especially phenyl. Also preferred are these aryl substituted with lower alkyl or lower alkoxy, especially methyl or methoxy; preferred examples mclude 4-mefhylphenyl, 4-methoxyphenyl, 5-methylfuryl, and 3,5-d ⁇ methylfuryl.
- —Rl is alkyl, it is preferably selected from substituted and unsubstituted, preferably unsubstituted, C1-C18 alkyl, more preferably C1-C12, still more preferably C1-C8, more preferably still saturated, straight cham Cl, C2, C3, C4, C5, C6, C7 or C8.
- --R2 is aryl, it is preferably selected from substituted and unsubstituted, preferably unsubstituted, 2-furyl, 3-furyl, 2-th ⁇ enyl, 3-th ⁇ enyl, 2-pyrrolyl, 3-pyrrolyl and phenyl, more preferably from 2-furyl, 2-th ⁇ enyl, 2-pyrrolyl and phenyl; more preferably 2-furyl, and especially phenyl. Also preferred are these aryl substituted with lower alkyl or lower alkoxy, especially methyl or methoxy; preferred examples mclude 4-methylphenyl, 4-methoxyphenyl, 5-methylfuryl, and 3,5-d ⁇ methylfuryl
- — R2 is alkyl, it is preferably selected from substituted and unsubstituted, preferably unsubstituted, C1-C18 alkyl, more preferably C1-C12, still more preferably C1-C8, more preferably still saturated, straight cham Cl, C2, C3, C4, C5, C6, C7 or C8
- R4 is aryl, it is preferably a substituted or unsubstituted, preferably unsubstituted phenyl
- -R4 is alkyl, it is preferably selected from substituted and unsubstituted, preferably unsubstituted, C1-C18, more preferably C1-C6, more preferably C1-C2, more preferably Cl --R4 is more preferably hydrogen
- R3 is aryl, it is preferably a substituted or unsubstituted, preferably unsubstituted, phenyl
- --R3 is alkyl, it is preferably selected from substituted and unsubstituted, preferably unsubstituted, C1-C18 alkyl, more preferably C1-C12, even more preferably C1-C6, still more preferably C1-C8, and even still more preferably Cl
- --R3 is hydrogen
- --R6 When --R6 is aryl, it is preferably a substituted or unsubstituted, preferably unsubstituted, phenyl
- --R6 When --R6 is alkyl, it is preferably a substituted or unsubstituted, preferably unsubstituted, C1-C18 alkyl, more preferably C1-C12, more preferably C1-C6, more preferably C1-C8, more preferably Cl -R6 is more preferably hydrogen.
- Preferred oxime compounds for use m the present mvention include syn- and anti-forms or mixtures thereof.
- anti and anti refer to the positioning of the ⁇ OR3 group with respect to the ⁇ M group In the anti position, --OR3 is proximate to — M; m the syn position, — OR3 is distal to — M Approximately equal amounts of the syn- and anti- forms of the same compound are preferred mixtures
- Preferred compounds for use m the present mvention which conform to the above structural formula m clude d ⁇ -(2-furyl) ethanedione syn-monooxime, d ⁇ -(2-furyl)ethaned ⁇ one anti-monooxime, d ⁇ -(5- methyl-2-furyl) ethanedione syn-monooxime, d ⁇ -(5-ethyl-2-furyl) ethanedione syn-monooxime, d ⁇ -(4-ethyl- 2-furyl) ethanedione syn-monooxime, d ⁇ -(4-ethyl-2-furyl) ethanedione anti-monooxime, and d ⁇ -(5-ethyl-2- furyl) ethanedione anti-monooxime; more preferred are d ⁇ -(2-furyl) ethanedione syn-monooxime, d ⁇ -(
- the present mvention mclude syn or anti d ⁇ -(2-furyl)-2- mercapto ethaneone oxime, syn or anti d ⁇ -(2-furyl)-2-methylmercapto ethaneone oxime, syn or anti d ⁇ -(2- furyl) thioethaneone monooxime; more preferred are syn or anti d ⁇ -(2-furyl)-2-mercapto ethaneone oxime, and syn or anti d ⁇ -(2-furyl)-2-methylmercapto ethaneone oxime, more preferred is syn or anti d ⁇ -(2-furyl)-2- mercapto ethaneone oxime
- N-phenyl-2-oxopropanam ⁇ de oxime N-phenylmethyl-2-oxopropanarmde oxime, N-(2-furyl-5-mefhyl)-2-oxopropanam ⁇ de oxime, and N- (2-furyl)-2-oxopropanam ⁇ de oxime
- N-phenyl-2-oxopropanam ⁇ de oxime N-phenylmethyl-2-oxopropanam ⁇ de oxrme
- N-(2-furyl-5-methyl)-2-oxopropanarmde oxime still more preferred is N-phenyl-2-oxopropanam ⁇ de oxime.
- Additional oxnne compounds which are useful m the present mvention mclude lH- ⁇ ndole-2,3- d ⁇ one-3-oxime, l-methyl- ⁇ ndole-2,3-d ⁇ one-3, oxnne, l-ethyl-mdole-2,3-d ⁇ one-3-ox ⁇ me, l-propyl- ⁇ ndole-2,3- d ⁇ one-3-ox ⁇ me, l-phenyl-mdole-2,3-d ⁇ one-3-ox ⁇ me, and l-(4-ethylphenyl)-mdole-2,3-d ⁇ one-3-oxune; more preferred is lH- ⁇ ndole-2,3-d ⁇ one-3-ox ⁇ me, l-methyl- ⁇ ndole-2,3-d ⁇ one-3-ox ⁇ me and 1-ethyl- ⁇ ndole-2,3- d ⁇ one-3-ox ⁇ me, more preferred is
- oxime compounds useful m the present mvention named above, the lack of a designation of syn- or anti- is nonspecific and means either form alone or a mixture of the two.
- Another preferred oxnne compound useful in the present mvention has the following structural formula'
- -R7 is hydrogen or from 0 to 5 alkyl substituents
- -R8 is C1-C8 alkyl
- --R7 are hydrogen or lower alkyls, more preferably C1-C3, especially methyl.
- -R7 are saturated when it is alkyl.
- -R7 are unsubstituted and straight cham when it is alkyl.
- Preferred -R7 is hydrogen or a mono-substituent, preferably m the 4- position
- Preferred -R8 is saturated Preferred -R8 is unsubstituted.
- Preferred -R8 is C1-C3, especially Cl
- the oxime compound is 1 -phenyl- l,2-propaned ⁇ one-2 -oxnne.
- the oxnne compound may have the following structural formula-
- each X is independently O or S, --R7 is from 1 to 3 alkyl substituents, and -R8 is C4-C8 alkyl
- Preferred X is O
- Preferred -R7 are m the 3-pos ⁇ t ⁇ on and/or 5-pos ⁇ t ⁇ on
- Preferred -R7 is a mono- substituent m the 5-pos ⁇ t ⁇ on; otherwise preferred -R7 and -R8 are as provided above
- the oxime compound useful m the present mvention has the following structure-
- each X is mdependently O or S, no more than one -R9 is hydrogen, and one or both -R9 are mdependently from 1 to 3 alkyl substituents
- Preferred X is O
- Preferred -R9 are lower alkyl, preferably C1-C3, especially methyl Preferred -R9 are saturated Preferred -R9 are unsubstituted.
- Preferred -R9 are straight cham
- Preferred -R9 are m the 3-pos ⁇ t ⁇ on and/or the 5-pos ⁇ t ⁇ on Preferred -R9 are mono- substituents m the 5-pos ⁇ t ⁇ on.
- the oxime compound of the present mvention may also have the following ⁇ -diamine compound structural formula
- each --R1 is mdependently selected from the group consisting of alkyl, aryl, heteroaryl and heterocyclic, or the — Rl's are covalently bonded together to form a cyclic alkyl or heterocyclic ⁇ ng
- — R2 and - R3 are — OR4, m which case there is no bond or a polar bond between -R2 and the mtrogen covalently bonded to — R3,
- both -Rl 's are the same moiety
- both — R4 's are the same moiety
- -Rl is aryl
- -Rl is preferably selected from substituted and unsubstituted, preferably unsubstituted, 2-hydroxyphenyl and phenyl
- —Rl is preferably selected from substituted and unsubstituted, preferably unsubstituted, 2-furyl, 3-furyl, 2-th ⁇ enyl, 3-fh ⁇ enyl, 2-pyrrolyl, 2- ⁇ madazolyl, 1-pyrazolyl, 2-pyrazmyl, 2- py ⁇ midinyl, 3-py ⁇ dazmyl, 3- ⁇ soqu ⁇ nolyl, 8-pu ⁇ nyl, 1-phthalaz ⁇ nyl, 2-qu ⁇ noxal ⁇ nyl, 3-fi ⁇ razanyl, 3- lsoxazolyl, 2-tetrazolyl and 5-tetrazolyl, more preferably from 2-furyl, 3-furyl, 2-th ⁇ enyl, 3-th ⁇ enyl and 2- pyrrolyl, more preferably still from 2-furyl and 3-furyl Most preferably -Rl is 2-furyl
- --R1 is heterocyclic
- --R1 is preferably the saturated analog of the preferred heteroaryls specified m the previous paragraph, most preferred is 2-tetrahydrofuryl
- — Rl is alkyl
- — Rl is preferably selected from substituted and unsubstituted, preferably unsubstituted, C1-C20 alkyl, more preferably C1-C18, more preferably C1-C12, more preferably still Cl- C6, more preferably C1-C2, most preferably Cl Preferred alkyl — Rl 's are alkanyls Preferred alkanyls are straight cham
- each substituent is preferably selected from alkyl and aryl
- the substituent is preferably selected from C1-C20 alkyl, more preferably C1-C18, more preferably C1-C12, more preferably still C1-C6, more preferably C1-C2, most preferably Cl
- the substituent is an aryl, it is preferably phenyl
- Prefe ⁇ ed oxime compounds which are useful m the present mvention m clude those havmg the following ⁇ -diamine structural formula
- Prefe ⁇ ed oxime compounds useful m the present mvention m clude those havmg the following - diamine structural formula
- — R4 is aryl, it is unsubstituted or substituted, preferably unsubstituted, preferably -R4 is phenyl
- the substituent is preferably —OH
- -R4 is alkyl
- it is unsubstituted or substituted, preferably unsubstituted, preferably selected from Cl -C20, more preferably C2-C18, more preferably C2-C12, more preferably C2-C6, more preferably still C2-C4, most preferably C2
- Preferred oxnne compounds useful m the present mvention mclude d ⁇ -(2-fury ⁇ ) ethanedione amphi- dioxime, d ⁇ -(5-methyl-2-furyl) ethanedione amphi-dioxime, d ⁇ -(4-methyl-2-furyl) ethanedione amphi- dioxime, d ⁇ -(5-ethyl-2-furyl) ethanedione amphi-dioxime, d ⁇ -(4-ethyl-2-furyl) ethanedione amphi-dioxime, d ⁇ -(5-propyl-2-furyl) ethanedione amphi-dioxime, and d ⁇ -(4-propyl-2-furyl) ethanedione amphi-dioxime, more prefe ⁇ ed are d ⁇ -(2-furyl) ethane-dione
- d ⁇ -(4-methyl-2-furyl) ethanedione amphi-dioxime Compounds also prefe ⁇ ed for use in the present mvention mclude d ⁇ -(2-th ⁇ enyl) ethanedione amphi-dioxime, d ⁇ -(5-mefhyl-2-fh ⁇ enyl) ethanedione amphi-dioxime, d ⁇ -(4-methyl-2-th ⁇ enyl) ethanedione amphi-dioxime, d ⁇ -(5-ethyl-2-tmenyl) ethanedione amphi-dioxime, and d ⁇ -(5-propyl-2-th ⁇ enyl) ethanedione ampmdtoxime, more prefe ⁇ ed are d ⁇ -(2-th ⁇ enyl) ethanedione amphi-dioxime, d ⁇ -(5-methyl-2-
- d ⁇ -(4-mefhyl-2-th ⁇ enyl) ethanedione amphi-dioxime Compounds also prefe ⁇ ed for use m the present mvention mclude d ⁇ -(2 -py ⁇ olyl) ethanedione amphi-dioxime, d ⁇ -(5-methyl-2-pyrrolyl) ethanedione amphi-dioxime, d ⁇ -(4-methyl-2-pyrrolyl) ethanedione amphi-dioxnne, d ⁇ -(5-efhyl-2-py ⁇ olyl) ethanedione amphi-dioxime, d ⁇ -(4-ethyl-2-pyrrolyl) ethanedione amphi-dioxime, d ⁇ -(5-propyl-2-py ⁇ olyl) ethanedione ampm-dioxm e
- Compounds also prefe ⁇ ed for use m the present mvention include d ⁇ -(l-methyl-2-py ⁇ olyl) ethanedione amphi-dioxime, d ⁇ -(l,5-d ⁇ methyl-2 -py ⁇ olyl) ethanedione amphi-dioxime, d ⁇ -(l-mefhyl-5-et ⁇ ryl- 2-pyrrolyl) ethanedione amphi-dioxime, d ⁇ -(l-methyl-5-propyl-2 -pyrrolyl) ethanedione amphi-dioxime, and d ⁇ (l-methyl-2-py ⁇ olyl) ethane
- amphi form is prefe ⁇ ed, mixtures of it with other forms (anti and/or syn) can be utilized, especially mixtures with approximately equal content of amphi and anti forms
- amphi form is prefe ⁇ ed
- mixtures of it with other forms can be utilized, especially mixtures with approximately equal content of amphi and anti forms
- Representative structures include- d ⁇ -(4-ethylphenyl) ethanedione amphi-dioxime and
- compositions of the present mvention are mixtures of any of the above compounds
- a compound also prefe ⁇ ed for use m the present mvention is amphi- 1 ,2-cyclohexaned ⁇ one, which is represented by the following structure
- compositions of the present mvention are mixtures of the above oxnne compounds Typically such mixtures are about half amphi-form and about half anti-form with very little (less than about 2%) syn- form
- any such mixture is preferably at least 40% amphi-form, more preferably at least 60% amphi-form, more preferably still at least 80% amphi-form
- Another aspect of the present mvention relates to oxnne compounds havmg the ⁇ -diamine structural formula
- ⁇ B is mdependently selected from the group consistmg of alkyl, aryl, or heteroaryl, preferably alkyl, more preferably C2-C20 alkyl, more preferably a C2-C6 alkyl, more preferably ethyl ⁇ B is preferably bonded to the 4-pos ⁇ t ⁇ on
- Another aspect of the present mvention relates to oxnne compounds havmg the ⁇ -diaimne structural formula
- ⁇ B is preferably bonded to the 5-pos ⁇ t ⁇ on
- Another aspect of the present mvention relates to oxime compounds havmg the structural formula
- — B is preferably bonded to the 5-pos ⁇ t ⁇ on
- Most prefe ⁇ ed oxnne compounds of the present mvention are selected from the group consistmg of d ⁇ -(2-furyl) ethanedione syn-monooxime, d ⁇ -(2-furyl) ethanedione anti-monooxime, d ⁇ -(2-furyl) ethanedione amphi-dioxime, d ⁇ -(2-furyl) ethanedione syn-dioxime, d ⁇ -(2-furyl) ethanedione anti-dioxime, 1- phenyl-l,2-propaned ⁇ one-2-ox ⁇ me, and combinations thereof
- Compositions of this mvention preferably contam from about 0 001% to about 20%, of the oxime compound, more preferably from or about 0 01% to about 10%, even more preferably from about 0.1% to about 5%, and most preferably from about 0.5% to about 5%, by weight of the composition. Derma
- the topical compositions of the present mvention also compnse a dermatologically acceptable carner for the oxime compound
- a dermatologically acceptable carner for the oxime compound
- the phrase "dermatologically acceptable earner”, as used herem means that the carner is suitable for topical application to mammalian keratinous tissue, has good aesthetic properties, is compatible with the actives of the present mvention and any other components, and will not cause any untoward safety or toxicity concerns.
- a safe and effective amount of earner is from about 50% to about 99.99%, preferably from about 80% to about 99 9%, more preferably from about 90% to about 98%, and most preferably from about 90%) to about 95% of the composition.
- the carner can be m a wide vanety of forms
- emulsion earners mcludmg, but not limited to, oil-in-water, water-in-o ⁇ , water-m-oil-in-water, and oil-in-water-in-silicone emulsions, are useful herem
- Prefe ⁇ ed earners compnse an emulsion such as oil-in-water emulsions, water-m-oil emulsions, and water-m-sihcone emulsions.
- a given component will distribute primarily mto either the water or oil/sihcone phase, dependmg on the water solub ⁇ ity/dispersibility of the component m the composition
- the oxime compound distributes pnmanly mto the oil phase. Oil-in-water emulsions are especially prefe ⁇ ed.
- Emulsions accordmg to the present invention generally contam a solution as described above and a lipid or oil
- Lipids and oils may be denved from animals, plants, or petroleum and may be natural or synthetic (i.e., man-made).
- Prefe ⁇ ed emulsions also contam a humectant, such as glycerin.
- Emulsions will preferably further contam from about 1% to about 10%, more preferably from about 2% to about 5%, of an emulsifier, based on the weight of the carner.
- Emulsifiers may be nonionic, anionic or canonic. Suitable emulsifiers are disclosed m, for example, U.S.
- Patent 3,755,560 issued August 28, 1973, Dickert et al.
- U.S Patent 4,421,769 issued December 20, 1983, Dixon et al
- McCutcheon's Detergents and Emulsifiers North American Edition, pages 317-324 (1986).
- the emulsion may also contam an anti-foaming agent to minimize foaming upon application to the keratmous tissue.
- Ann-foaming agents mclude high molecular weight sihcones and other matenals well known in the art for such use.
- Suitable emulsions may have a wide range of viscosities, dependmg on the desned product form
- Prefe ⁇ ed water-m-sihcone and oil-in-water emulsions are descnbed m greater detail below a) Water-in-silicone emulsion
- Prefe ⁇ ed water-m-sihcone emulsions of the present mvention comprise from about 1% to about 60%), preferably from about 5% to about 40%, more preferably from about 10% to about 20%, by weight of a contmuous silicone phase
- the continuous silicone phase exists as an external phase that contains or surrounds the discontinuous aqueous phase descnbed hereinafter
- the contmuous silicone phase contains a polyorganosiloxane oil
- a prefe ⁇ ed water-in-sihcone emulsion system is formulated to provide an oxidatively stable vehicle for the optional retinoid
- the continuous silicone phase of these prefe ⁇ ed emulsions compnses between about 50% and about 99 9% by weight of organopolysiloxane oil and less than about 50% by weight of a non-silicone oil
- the contmuous silicone phase compnses at least about 50%, preferably from about 60% to about 99 9%, more preferably from about 70% to about 99 9%, and even more preferably from about 80% to about 99 9%, polyorganosiloxane oil by weight of the contmuous silicone phase, and up to about 50%) non-silicone oils, preferably less about 40%, more preferably less than about 30%, even more preferably less than about 10%, and most preferably less than about 2%, by weight of the contmuous silicone phase Concentrations of
- the organopolysiloxane oil for use m the composition may be volatile, non-volatile, or a mixture of volatile and non-volatile silicones
- nonvolatile refers to those sihcones that are liquid under ambient conditions and have a flash pomt (under one atmosphenc of pressure) of or greater than about 100°C
- volatile refers to all other silicone oils
- Suitable organopolysiloxanes can be selected from a wide vanety of sihcones spanning a broad range of volatilities and viscosities Examples of suitable organopolysiloxane oils mclude polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes
- Polyalkylsiloxanes useful in the composition herem mclude polyalkylsiloxanes with viscosities of from about 0 5 to about 1,000,000 centistokes at 25°C
- Such polyalkylsiloxanes can be represented by the general chemical formula R3S ⁇ O[R2S ⁇ O]xS ⁇ R3 wherein R is an alkyl group havmg from one to about 30 carbon atoms (preferably R is methyl or ethyl, more preferably methyl, also mixed alkyl groups can be used m the same molecule), and x is an integer from 0 to about 10,000, chosen to achieve the desired molecular weight which can range to over about 10,000,000
- Commercially available polyalkylsiloxanes mclude the polydimefhylsiloxanes, which are also known as dimethicones, examples of which mclude the Vicasil® senes sold by General Electnc Company and the Dow Corning® 200 senes sold by Dow Corning Corporation Specific
- Suitable dimethicones include those represented by the chemical formula (CH3)3S ⁇ O[(CH3)2S ⁇ O]x[CH3RS ⁇ O]yS ⁇ (CH3)3 wherem R is straight or branched cham alkyl havmg from two to about 30 carbon atoms and x and y are each mtegers of 1 or greater selected to achieve the desned molecular weight which can range to over about 10,000,000 Examples of these alkyl-substituted dimethicones mclude cetyl dimethicone and lauryl dimethicone.
- Cyclic polyalkylsiloxanes suitable for use m the composition m clude those represented by the chemical formula [S ⁇ R2-0]n wherem R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and n is an mteger from about 3 to about 8, more preferably n is an mteger from about 3 to about 7, and most preferably n is an mteger from about 4 to about 6.
- n 4 and 5
- matenals such as tnmethylsiloxysilicate, which is a polymeric matenal co ⁇ esponding to the general chemical formula [(CH2)3S ⁇ 01/2]x[S ⁇ 02]y, wherem x is an mteger from about 1 to about 500 and y is an mteger from about 1 to about 500
- tnmethylsiloxysilicate is sold as a mixture with dimethicone as Dow Corning® 593 fluid
- Dimefhiconols are also suitable for use m the composition These compounds can be represented by the chemical formulas R3S ⁇ O[R2S ⁇ O]xS ⁇ R20H and HOR2S ⁇ O[R2S ⁇ O]xS ⁇ R20H wherem R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and x is an mteger from 0 to about 500, chosen to achieve the desned molecular weight.
- Commercially available dimefhiconols are typically sold as mixtures with dimethicone or cyclomethicone (e.g. Dow Corning® 1401, 1402, and 1403 fluids).
- Polyalkylaryl siloxanes are also suitable for use m the composition Polymethylphenyl siloxanes havmg viscosities from about 15 to about 65 centistokes at 25°C are especially useful.
- organopolysiloxanes selected from the group consistmg of polyalkylsiloxanes, alkyl substituted dimethicones, cyclomethicones, tnmethylsiloxysihcates, dimefhiconols, polyalkylaryl siloxanes, and mixtures thereof More prefe ⁇ ed for use herem are polyalkylsiloxanes and cyclomethicones. Prefe ⁇ ed among the polyalkylsiloxanes are dimethicones
- the contmuous silicone phase may contam one or more non-silicone oils.
- Suitable non-silicone oils have a melting pomt of about 25°C or less under about one atmosphere of pressure
- Examples of non-silicone oils suitable for use m the contmuous silicone phase are those well known m the chemical arts m topical personal care products m the form of water-m-oil emulsions, e g , mineral oil, vegetable oils, synthetic oils, semisynthetic oils, etc (n) Dispersed aqueous phase
- compositions of the present mvention compnse from about 30% to about 90%, more preferably from about 50% to about 85%, and most preferably from about 70% to about 80% of a dispersed aqueous phase
- dispersed phase is a term well-known to one skilled m the art which means that the phase exists as small particles or droplets that are suspended m and surrounded by a contmuous phase
- the dispersed phase is also known as the internal or discontinuous phase
- the dispersed aqueous phase is a dispersion of small aqueous particles or droplets suspended m and surrounded by the continuous silicone phase described herembefore
- the aqueous phase can be water, or a combmation of water and one or more water soluble or dispersible ingredients
- noisyimihng examples of such optional ingredients mclude thickeners, acids, bases, salts, chelants, gums, water-soluble or dispersible alcohols and polyols, buffers, preservatives, sunscreening agents, colormgs, and the like
- compositions of the present mvention will typically comprise from about 25% to about 90%, preferably from about 40% to about 80%, more preferably from about 60%> to about 80%, water in the dispersed aqueous phase by weight of the composition
- Emulsifier for dispersmg the aqueous phase
- the water-in-sihcone emulsions of the present mvention preferably compnse an emulsifier
- the composition contams from about 0 1% to about 10% emulsifier, more preferably from about 0 5% to about 7 5%, most preferably from about 1% to about 5%, emulsifier by weight of the composition
- the emulsifier helps disperse and suspend the aqueous phase within the contmuous silicone phase
- a wide vanety of emulsifying agents can be employed herem to form the prefe ⁇ ed water-in-sihcone emulsion
- emulsifying agents can be used m the composition, provided that the selected emulsifying agent is chemically and physically compatible with essential components of the composition, and provides the desired dispersion charactenshcs
- Suitable emulsifiers mclude silicone emulsifiers, non-sihcon-containing emulsifiers, and mixtures thereof, known by those skilled m the art for use in topical personal care products
- these emulsifiers have an HLB value of or less than about 14, more preferably from about 2 to about 14, and most preferably from about 4 to about 14
- Emulsifiers havmg an HLB value outside of these ranges can be used m combmation with other emulsifiers to achieve an effective weighted average HLB for the combmation that falls within these ranges
- Silicone emulsifiers are prefe ⁇ ed A wide vanety of silicone emulsifiers are useful herem These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled m the art as silicone surfactants.
- Useful silicone emulsifiers mclude dimethicone copolyols These matenals are polydimethyl siloxanes which have been modified to mclude polyether side chains such as polyethylene oxide chams, polypropylene oxide chains, mixtures of these chams, and polyether chams contammg moieties denved from both ethylene oxide and propylene oxide Other examples mclude alkyl-modified dimethicone copolyols, 1 e , compounds which contam C2-C30 pendant side chams Still other useful dimethicone copolyols mclude matenals havmg vanous cationic, anionic, amphote ⁇ c, and zwit
- dimethicone copolyol emulsifiers useful herem can be descnbed by the following general structure
- R is C1-C30 straight, branched, or cyclic alkyl and R2 is selected from the group consisting of
- R3 and R4 are selected from the group consistmg of H and Cl- C6 straight or branched cham alkyl such that R3 and R4 are not simultaneously the same, and m, o, x, and y are selected such that the molecule has an overall molecular weight from about 200 to about 10,000,000, with m, o, x, and y bemg mdependently selected from mtegers of zero or greater such that m and o are not both simultaneously zero, and z bemg mdependently selected from mtegers of 1 or greater It is recognized that positional isomers of these copolyols can be achieved
- the chemical representations depicted above for the R2 moieties contammg the R3 and R4 groups are not meant to be limiting but are shown as such for convenience
- silicone surfactants as depicted m the structures m the previous paragraph wherem R2 is
- Nominating examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers herem mclude polydimethylsiloxane polyether copolymers with pendant polyethylene oxide sidechams, polydimethylsiloxane polyether copolymers with pendant polypropylene oxide sidechams, polydimethylsiloxane polyether copolymers with pendant mixed polyethylene oxide and polypropylene oxide sidechams, polydimethylsiloxane polyether copolymers with pendant mixed poly(ethylene)(propylene)ox ⁇ de sidechams, polydimethylsiloxane polyether copolymers with pendant organobetaine sidechams, polydimethylsiloxane polyether copolymers with pendant carboxylate sidechams, polydimethylsiloxane polyether copolymers with pendant quaternary ammonium sidechams, and also further modifications of the precedmg copolymers contammg pendant C2-C30 straight, branche
- Dimethicone copolyol emulsifiers useful herem are desc ⁇ bed, for example, m U S Patent No 4,960,764, to Figueroa, Jr et al , issued October 2, 1990, European Patent No EP 330,369, to SanoGueira, published August 30, 1989, G H Dahms, et al , "New Formulation Possibilities Offered by Silicone Copolyols," Cosmetics & Toiletries, vol 110, pp 91-100, March 1995, M E Carlotti et al , "Optimization of W/O-S Emulsions And Study Of The Quantitative Relationships Between Ester Structure And Emulsion Properties," J Dispersion Science And Technology, 13(3), 315-336 (1992), P Hameyer, "Comparative Technological Investigations of Orgamc and Organosihcone Emulsifiers m Cosmetic Water-m-Oil Emulsion Preparations," HAPPI 28(4), pp 88-128 (1991),
- non-sihcone-containing emulsifiers useful herem are vanous non-iomc and amomc emulsifying agents such as sugar esters and polyesters, alkoxylated sugar esters and polyesters, C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated denvatives of C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated ethers of C1-C30 fatty alcohols, polyglyceryl esters of C1-C30 fatty acids, C1-C30 esters of polyols, C1-C30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, and mixtures thereof
- Other suitable emulsifiers are descnbed, for example, m McCutcheon's, Detergents and Em
- Nonlimiting examples of these non-sihcone-containing emulsifiers mclude polyethylene glycol 20 sorbitan monolaurate (Polysorbate 20), polyethylene glycol 5 soya sterol, Steareth-20, Ceteareth-20, PPG-2 methyl glucose ether distearate, Cetefh-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamme cetyl phosphate, Polysorbate 60, glyceryl stearate, PEG- 100 stearate, polyoxyethylene 20 sorbitan tnoleate (Polysorbate 85), sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, steareth-20, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, diethanolamine cetyl phosphate, glyceryl stearate
- oil phase a hydrophobic, water-insoluble phase
- suitable earners compnsing oil-m-water emulsions are described m U S Pat No 5,073,371, to Turner, D J et al , issued Dec 17, 1991, and U S Pat No 5,073,372, to Turner, D J et al , issued Dec 17, 1991
- a prefe ⁇ ed oil-in-water emulsion compnses a structunng agent to assist m the formation of a liquid crystalline gel network structure
- the structunng agent assists m providmg rheological charactenstics to the composition which contribute to the stability of the composition
- the structunng agent may also function as an emulsifier or surfactant
- Prefe ⁇ ed compositions of this mvention comprise from about 0 5% to about 20%, more preferably from about 1% to about 10%, most preferably from about 1% to about 5%, by weight of the composition, of a structunng agent
- the preferred structunng agents of the present mvention are selected from the group consisting of steanc acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steanc acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol havmg an average of about 1 to about 21 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol havmg an average of about 1 to about 5 ethylene oxide units, and mixtures thereof More prefe ⁇ ed structunng agents of the present mvention are selected from the group consistmg of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol havmg an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of stearyl alcohol havmg an average of about 21 ethylene oxide units (steareth-21), the polyethylene glycol ether of cetyl alcohol havmg an average of about 2 ethylene
- the preferred oil-in- water emulsions compnse from about 0 05% to about 10%, preferably from about 1% to about 6%, and more preferably from about 1% to about 3% of at least one hydrophilic surfactant which can disperse the hydrophobic matenals m the water phase (percentages by weight of the topical carner)
- the surfactant at a minimum, must be hydrophilic enough to disperse m water
- Suitable surfactants include any of a wide vanety of known catiomc, anionic, zwittenomc, and amphotenc surfactants See, McCutcheon's, Detergents and Emulsifiers, North Amencan Edition (1986), published by Allured Publishing Corporation; U.S. Patent 5,011,681 ; U.S. Patent 4,421,769; and U.S. Patent 3,755,560; these references are incorporated herem by reference m their entirety.
- the exact surfactant chosen will depend upon the pH of the composition and the other components present.
- Prefe ⁇ ed are catiomc surfactants, especially dialkyl quaternary ammonium compounds, examples of which are descnbed m U.S. Patent 5,151,209; U.S. Patent 5,151,210, U.S. Patent 5,120,532; U.S. Patent 4,387,090, U.S. Patent 3,155,591 ; U.S. Patent 3,929,678; U.S. Patent 3,959,461; McCutcheon's, Detergents & Emulsifiers, (North American edition 1979) M.C.
- catiomc surfactants useful herem m include catiomc ammonium salts such as those havmg the formula:
- Rl is an alkyl group havmg from about 12 to about 30 carbon atoms, or an aromatic, aryl or alkaryl group havmg from about 12 to about 30 carbon atoms;
- R2, R3, and R4 are mdependently selected from hydrogen, an alkyl group havmg from about 1 to about 22 carbon atoms, or aromatic, aryl or alkaryl groups havmg from about 12 to about 22 carbon atoms; and
- X is any compatible amon, preferably selected from the group consisting of chlonde, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate, and mixtures thereof
- the alkyl groups of Rl, R2, R3, and R4 can also contam ester and/or ether linkages, or hydroxy or ammo group substituents (e.g.
- Rl is an alkyl group havmg from about 12 to about 22 carbon atoms
- R2 is selected from H or an alkyl group havmg from about 1 to about 22 carbon atoms
- R3 and R4 are mdependently selected from H or an alkyl group havmg from about 1 to about 3 carbon atoms
- X is as descnbed previously.
- Rl is an alkyl group havmg from about 12 to about 22 carbon atoms
- R2, R3, and R4 are selected from H or an alkyl group havmg from about 1 to about 3 carbon atoms
- X is as described previously.
- catiomc emulsifiers include amino-amides, wherem m the above structure Rl is alternatively R5CONH-(CH2)n, wherem R5 is an alkyl group havmg from about 12 to about 22 carbon atoms, and n is an mteger from about 2 to about 6, more preferably from about 2 to about 4, and most preferably from about 2 to about 3
- Nonlrmitmg examples of these catiomc emulsifiers mclude stearamidopropyl PG-dimonium chlonde phosphate, behenamidopropyl PG dimonium chlonde, stearamidopropyl ethyldimomum ethosulfate, stearamidopropyl dimethyl (mynstyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl
- Nonlmritmg examples of quaternary ammomum salt catiomc surfactants m clude those selected from the group consisting of cetyl ammomum chlonde, cetyl ammomum bromide, lauryl ammomum chlonde, lauryl ammomum bromide, stearyl ammomum chlonde, stearyl ammomum bromide, cetyl dimethyl ammomum chlonde, cetyl dimethyl ammomum bromide, lauryl dimethyl ammomum chlonde, lauryl dimethyl ammonium bromide, stearyl dimethyl ammomum chlonde, stearyl dimethyl ammomum bromide, cetyl tnmethyl ammomum chlonde, cetyl tnmethyl ammomum bromide, lauryl tnmethyl ammomum
- Additional quaternary ammonium salts mclude those wherem the C12 to C30 alkyl carbon cham is derived from a tallow fatty acid or from a coconut fatty acid
- tallow refers to an alkyl group denved from tallow fatty acids (usually hydrogenated tallow fatty acids), which generally have mixtures of alkyl chains in the C16 to C18 range.
- coconut refers to an alkyl group denved from a coconut fatty acid, which generally have mixtures of alkyl chams ⁇ n the C12 to C14 range.
- Examples of quaternary ammonium salts denved from these tallow and coconut sources mclude ditallow dimethyl ammomum chlonde, ditallow dimethyl ammomum methyl sulfate, di(hydrogenated tallow) dimethyl ammomum chloride, d ⁇ (hydrogenated tallow) dimethyl ammonium acetate, ditallow dipropyl ammomum phosphate, ditallow dimethyl ammomum nitrate, d ⁇ (coconutalkyl)d ⁇ methyl ammonium chlonde, d ⁇ (coconutalkyl)d ⁇ methyl ammomum bromide, tallow ammomum chlonde, coconut ammomum chlonde, stearamidopropyl PG-dimomum chlonde phosphate, stearamidopropyl ethyldmiomum ethosulfate, steara
- More preferred catiomc surfactants are those selected from the group consisting of behenamidopropyl PG dimonium chlonde, dilauryl dimethyl ammomum chlonde, distearyl dimethyl ammomum chlonde, dimynstyl dimethyl ammomum chlonde, dipalmityl dimethyl ammomum chlonde, distearyl dimethyl ammomum chlonde, stearamidopropyl PG-dimonium chlonde phosphate, stearamidopropyl ethyldiammomum ethosulfate, stearamidopropyl dimethyl (mynstyl acetate) ammomum chlonde, stearamidopropyl dimethyl cetearyl ammomum tosylate, stearamidopropyl dimethyl ammomum chloride, ste
- Most preferred catiomc surfactants are those selected from the group consistmg of behenamidopropyl PG dimonium chlonde, dilauryl dimethyl ammomum chlonde, distearyl dimethyl ammomum chlonde, dimynstyl dimethyl ammomum chlonde, dipalmityl dimethyl ammomum chlonde, and mixtures thereof
- a prefe ⁇ ed combmation of catiomc surfactant and structunng agent is behenamidopropyl PG dimomum chlonde and/or behenyl alcohol, wherem the ratio is preferably optimized to maintained to enhance physical and chemical stability, especially when such a combmation contams lomc and/or highly polar solvents
- sunscreenmg agents such as zmc oxide and octyl methoxycinnamate
- amomc surfactants are also useful herem See, e g , U S Patent No 3,929,678, to Laughlin et al , issued December 30, 1975, which is incorporated herem by reference m its entirety
- Nonlimmng examples of amomc surfactants mclude the alkoyl lsefhionates, and the alkyl and alkyl ether sulfates
- the alkoyl lsefhionates typically have the formula RCO-OCH2CH2S03M wherem R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, and M is a water-soluble cation such as ammomum, sodium, potassium and tnethanolamme Nominating examples of these lsethionates mclude those alkoyl lsethionates selected from the group consistmg of ammomum cocoyl lsethionate, sodium cocoyl l
- the alkyl and alkyl ether sulfates typically have the respective formulae ROS03M and RO(C2H40)xS03M, wherem R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, x is from about 1 to about 10, and M is a water-soluble cation such as ammomum, sodium, potassium and tnethanolamme
- R alkyl or alkenyl of from about 10 to about 30 carbon atoms
- x is from about 1 to about 10
- M is a water-soluble cation such as ammomum, sodium, potassium and tnethanolamme
- amomc surfactants are the water-soluble salts of the orgamc, sulfunc acid reaction products of the general formula
- R1-S03-M wherem Rl is chosen from the group consistmg of a straight or branched cham, saturated aliphatic hydrocarbon radical havmg from about 8 to about 24, preferably about 10 to about 16, carbon atoms, and M is a cation
- Still other amomc synthetic surfactants mclude the class designated as succinamates, olefin sulfonates havmg about 12 to about 24 carbon atoms, and ⁇ -alkyloxy alkane sulfonates Examples of these matenals are sodium lauryl sulfate and ammomum lauryl sulfate
- amomc matenals useful herem are soaps (I e alkali metal salts, e g , sodium or potassium salts) of fatty acids, typically havmg from about 8 to about 24 carbon atoms, preferably from about 10 to about 20 carbon atoms
- the fatty acids used m making the soaps can be obtamed from natural sources such as, for instance, plant or ammal-denved glycendes (e g , palm oil, coconut oil, soybean oil, castor oil, tallow, lard, etc )
- the fatty acids can also be synthetically prepared Soaps are descnbed m more detail m U S Patent No 4,557,853
- Amphotenc and zwittenomc surfactants are also useful herem
- Examples of amphote ⁇ c and zwittenomc surfactants which can be used m the compositions of the present mvention are those which are broadly descnbed as denvatives of aliphatic secondary and tertiary amines m which the aliphatic radical can be straight or branched cham and wherem one of the aliphatic substituents contams from about 8 to about 22 carbon atoms (preferably C8 - C18) and one contams an amomc water solubilizmg group, e g , carboxy, sulfonate, sulfate, phosphate, or phosphonate
- Examples are alkyl rmino acetates, and lminodialkanoates and aminoalkanoates of the formulas RN[CH2)mC02M]2 and RNH(CH2)mC02M wherem m is from 1 to 4, R is
- betames examples include the higher alkyl betames, such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymefhyl betaine, lauryl dimethyl alphacarboxyethyl betame, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betame (available as Lonzaine 16SP from Lonza Corp ) lauryl b ⁇ s-(2-hydroxyethyl) carboxymethyl betame, stearyl b ⁇ s-(2-hydroxypropyl) carboxymethyl betame, oleyl dimethyl gamma-carboxypropyl betame, lauryl b ⁇ s-(2-hydroxypropyl)alpha-carboxyethyl betame, coco dimethyl sulfopropyl betame, stearyl dimethyl sulfopropyl betame, lauryl dimethyl sulfoethyl betame
- amphotenc and zwittenomc surfactants mclude the sultames and hydroxysultames such as cocamidopropyl hydroxysultaine (available as Mirataine CBS from Rhone-Poulenc), and the alkanoyl sarcosinates co ⁇ espondmg to the formula RCON(CH3)CH2CH2C02M wherem R is alkyl or alkenyl of about 10 to about 20 carbon atoms, and M is a water-soluble cation such as ammomum, sodium, potassium and tnalkanolamme (e g , tnethanolamme), a preferred example of which is sodium lauroyl sarcosinate (m) Water
- the prefe ⁇ ed oil-in-water emulsion compnses from about 25% to about 98%, preferably from about 65% to about 95%, more preferably from about 70% to about 90%> water by weight of the topical carner
- the hydrophobic phase is dispersed m the contmuous aqueous phase
- the hydrophobic phase may contam water insoluble or partially soluble matenals such as are known m the art, mcludmg but not limited to the sihcones descnbed herem m reference to sihcone-in-water emulsions, and other oils and hpids such as descnbed above m reference to emulsions.
- compositions of the subject mvention may compnse a dermatologically acceptable emollient
- emollient refers to a matenal useful for the prevention or relief of dryness, as well as for the protection of the skm
- emollient refers to a matenal useful for the prevention or relief of dryness, as well as for the protection of the skm
- a wide vanety of suitable emollients are known and may be used herem. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol.
- Glycerm is preferably used m an amount of from or about 0.001 to or about 20%, more preferably from or about 0 01 to or about 10%, most preferably from or about 0.1 to or about 5%, e.g., 3%
- Lotions and creams accordmg to the present invention generally compnse a solution earner system and one or more emollients Lotions typically compnse from about 1% to about 20%, preferably from about 5% to about 10%, of emollient, from about 50% to about 90%, preferably from about 60% to about 80%, water; and farnesol in the above descnbed amounts
- a cream typically compnses from about 5% to about 50%), preferably from about 10% to about 20%, of emollient, from about 45% to about 85%, preferably from about 50%> to about 75%, water; and the farnesol m the above descnbed amounts.
- Ointments of the present mvention may compnse a simple carner base of animal or vegetable oils or semi-solid hydrocarbons (oleagmous); absorption ointment bases which absorb water to form emulsions, or water soluble earners, e.g., a water soluble solution earner Ointments may further compnse a thickening agent, such as described m Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol 1, pp 72-73 (1972), incorporated herem by reference, and/or an emollient
- an ointment may compnse from about 2% to about 10% of an emollient, from about 0 1% to about 2%> of a thickening agent, and farnesol m the above descnbed amount
- compositions of this mvention useful for cleansing are formulated with a suitable earner, e.g., as descnbed above, and preferably contam, m addition to the oxnne compound m the above descnbed amounts, from about 1% to about 90%, more preferably from about 5% to about 10%, of a dermatologically acceptable surfactant
- the surfactant is suitably selected from amomc, nonionic, zwittenomc, amphotenc and ampholytic surfactants, as well as mixtures of these surfactants
- Such surfactants are well known to those skilled m the detergency art
- Nonlumtmg examples of possible surfactants mclude ⁇ soceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, and sodium lauryl sulfate.
- the cleansing compositions can optionally contam, at then- art-established levels, other matenals which are conventionally used m cleansing compositions.
- the physical form of the cleansmg compositions is not cntical
- the compositions can be, for example, formulated as toilet bars, liquids, shampoos, bath gels, hair conditioners, hair tomes, pastes, or mousses.
- Toilet bars are most prefe ⁇ ed smce this is the form of cleansmg agent most commonly used to wash the skm Rinse-off cleansmg compositions, such as shampoos, require a delivery system adequate to deposit sufficient levels of actives on the skm and scalp A prefe ⁇ ed delivery system mvolves the use of insoluble complexes
- U.S. Patent 4,835,148, Barford et al. issued May 30, 1989.
- the term "foundation” refers to a liquid, semi-liquid, semi-solid, or solid skm cosmetic which includes, but is not limited to lotions, creams, gels, pastes, cakes, and the like Typically the foundation is used over a large area of the skm, such as over the face, to provide a particular look.
- Foundations are typically used to provide an adherent base for color cosmetics such as rouge, blusher, powder and the like, and tend to hide skm imperfections and impart a smooth, even appearance to the skm Foundations of the present invention mclude a dermatologically acceptable carner for the farnesol and may mclude conventional ingredients such as oils, colorants, pigments, emollients, fragrances, waxes, stabilizers, and the like Exemplary earners and such other ingredients which are suitable for use herem are descnbed, for example, m copendmg patent application Serial No. 08/430,961, filed on April 28, 1995 m the names of Marcia L Canter, Bram D Barford, and Brian D. Hof ⁇ chter, and U.K. Patent Application GB 2274585-A, published on Jan. 23, 1993.
- Optional Components are typically used to provide an adherent base for color cosmetics such as rouge, blusher, powder and the like, and tend to hide skm imperfections and impart a smooth, even appearance to
- compositions of the present invention may contam a variety of other ingredients such as are conventionally used m a given product type provided that they do not unacceptably alter the benefits of the mvention.
- the optional components should be suitable for application to mammalian keratmous tissue, that is, when incorporated mto the composition they are suitable for use m contact with mammalian keratmous tissue, especially that of humans, without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound medical judgment.
- abrasives e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
- anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
- anti-acne agents e g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
- anti-acne agents e e e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
- anti-acne agents e e eugenol, menthyl lactate, witch hazel distillate
- antimicrobial agents e g
- the actives useful herem can be categorized by the benefit they provide or by then postulated mode of action
- the actives useful herem can m some mstances provide more than one benefit or operate via more than one mode of action Therefore, classifications herem are made for the sake of convemence and are not mtended to limit the active to that particular application or applications listed
- a safe and effective amount of a desquamation active may be added to the compositions of the present mvention, more preferably from about 0.1%) to about 10%, even more preferably from about 0 2% to about 5%, also preferably from about 0.5% to about 4%, by weight of the composition
- Desquamation actives enhance the skm appearance benefits of the present mvention For example, the desquamation actives tend to improve the texture of the skm (e.g , smoothness)
- One desquamation system that is suitable for use herem comprises sulfhydryl compounds and zwittenomc surfactants and is descnbed m copendmg application Senal No 08/480,632, filed on June 7, 1995 m the name of Donald L.
- compositions of the present mvention may compnse a safe and effective amount of one or more anti-acne actives.
- useful anti-acne actives mclude resorcmol, sulfur, salicylic acid, erythromycin, zmc, etc
- suitable anti-acne actives are descnbed m further detail m U. S. Patent No. 5,607,980, issued to McAtee et al, on March 4, 1997.
- compositions of the present mvention may further compnse a safe and effective amount of one or more anti-wnnkle actives or anti-atrophy actives
- Exemplary anti-wnnkle/anti-atrophy actives suitable for use m the compositions of the present mvention mclude sulfur-containing D and L ammo acids and their denvatives and salts, particularly the N-acetyl denvatives, a preferred example of which is N-acetyl-L- cysteme; thiols, e.g.
- ethane thiol hydroxy acids (e.g., glycohc acid, lactic acid, and the like), phytic acid, lipoic acid; lysophosphatidic acid, skm peel agents (e g., phenol and the like), vitamin B3 compounds and retmoids which enhance the keratmous tissue appearance benefits of the present mvention, especially in regulating keratmous tissue condition, e.g., skm condition.
- compositions of the present mvention may compnse a safe and effective amount of a vitamm B3 compound.
- Vitamm B3 compounds are particularly useful for regulating skm condition as descnbed m co-pendmg U S.
- Application Senal No 08/834,010, filed Apnl 11, 1997 (co ⁇ espondmg to international publication WO 97/39733 Al, published October 30, 1997).
- compositions of the mstant mvention preferably comprise from about 0.01% to about 50%, more preferably from about 0.1% to about 10%, even more preferably from about 0.5% to about 10%>, and still more preferably from about 1% to about 5%>, most preferably from about 2% to about 5%, by weight of the composition, of the vitamm B3 compound
- vitamin B3 compound means a compound havmg the formula
- R is - CONH2 (i.e , niacinamide), - COOH (I e., nicotimc acid) or - CH20H (l e , nicotinyl alcohol); derivatives thereof; and salts of any of the foregomg
- Exemplary derivatives of the foregomg vitamm B3 compounds mclude nicotimc acid esters, mcludmg non-vasodilatmg esters of nicotmic acid (e g., tocopheryl mcotmate), nicotinyl ammo acids, mcotmyl alcohol esters of carboxylic acids, nicotimc acid N-oxide and niacinamide N-oxide
- Suitable vitamm B3 compounds are well known m the art and are commercially available from a number of sources, e g., the Sigma Chemical Company (St Louis, MO), ICN Biomedicals, Inc. (Irvin, CA) and Aldnch Chemical Company (Milwaukee, WI)
- the vitamm compounds may be mcluded as the substantially pure matenal, or as an extract obtained by suitable physical and or chemical isolation from natural (e.g , plant) sources
- Prefened vitamin B3 compounds are niacinamide, tocopherol mcotmate, and mixtures thereof b) Retmoids
- compositions of the present mvention may also compnse a retinoid.
- retinoid mcludes all natural and/or synthetic analogs of Vitamin A or retinol-hke compounds which possess the biological activity of Vitamin A m the skm as well as the geometric isomers and stereoisomers of these compounds.
- the retinoid is preferably retinol, retmol esters (e g., C2 - C22 alkyl esters of retmol, mcludmg retinyl palmitate, rehnyl acetate, retmyl propionate), retinal, and/or rettnoic acid (mcludmg all-trans retmoic acid and/or 13-c ⁇ s-ret ⁇ no ⁇ c acid), more preferably retmoids other than retmoic acid
- retmol esters e g., C2 - C22 alkyl esters of retmol, mcludmg retinyl palmitate, rehnyl acetate, retmyl propionate
- retinal and/or rettnoic acid (mcludmg all-trans retmoic acid and/or 13-c ⁇ s-ret ⁇ no ⁇ c acid), more preferably ret
- retmoids are tocopheryl-retinoate [tocopherol ester of retmoic acid (trans- or cis-), adapalene ⁇ 6-[3-(l-adamanty ⁇ )-4- methoxyphenyl]-2-naphtho ⁇ c acid ⁇ , and tazarotene (ethyl 6-[2-(4,4-dimethylfhiochroman-6-yl)- ethynyljmcotmate)
- Prefe ⁇ ed retmoids are retmol, retmyl palmitate, retmyl acetate, retmyl propionate, retmal and combinations thereof.
- the retmoid may be mcluded as the substantially pure matenal, or as an extract obtamed by suitable physical and or chemical isolation from natural (e g , plant) sources
- the retmoid is preferably substantially pure, more preferably essentially pure.
- compositions of this mvention may contam a safe and effective amount of the retinoid, such that the resultant composition is safe and effective for regulatmg keratmous tissue condition, preferably for regulatmg visible and/or tactile discontinuities m skm, more preferably for regulatmg signs of skm agmg, even more preferably for regulatmg visible and/or tactile discontinuities m skm texture associated with skm agmg
- the compositions preferably contam from or about 0 005% to or about 2%, more preferably 0 01% to or about 2%, retmoid Retmol is most preferably used m an amount of from or about 0.01% to or about 0.15%, retmol esters are most preferably used m an amount of from or about 0.01% to or about 2% (e g., about 1%); retmoic acids are most preferably used m an amount of from or about 0.01% to or about 0.25%, tocopheryl
- compositions of the present mvention contam both a retmoid and a Vitamin B3 compound
- the retmoid is preferably used m the above amounts
- the vitamm B3 compound is preferably used m an amount of from or about 0 1% to or about 10%, more preferably from or about 2% to or about 5%
- compositions of the present mvention may mclude a safe and effective amount of an anti- oxidant/radical scavenger.
- the anti-oxidant/radical scavenger is especially useful for providmg protection agamst UV radiation which can cause mcreased scalmg or texture changes m the stratum corneum and against other envnonmental agents which can cause skm damage.
- a safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject mvention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition
- Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid denvatives (e.g , magnesium ascorbyl phosphate), tocopherol (vitamm E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and then salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxyhc acid (commercially available under the tradename TroloxR), gallic acid and its alkyl esters, especially propyl gallate, unc acid and its salts and alkyl esters, sorbic acid and its salts, hpoic acid, amines (e.g., N,N-d ⁇ ethylhydroxylamme, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fuma ⁇ c acid and its salt
- compositions of the present mvention may also compnse a safe and effective amount of a chelator or chelatmg agent
- chelator or “chelatmg agent” means an active agent capable of removmg a metal ion from a system by forming a complex so that the metal ion cannot readily participate m or catalyze chemical reactions
- the inclusion of a chelatmg agent is especially useful for providmg protection agamst UV radiation which can contribute to excessive scalmg or skm texture changes and agamst other envnonmental agents which can cause skm damage
- a safe and effective amount of a chelatmg agent may be added to the compositions of the subject mvention, preferably from about 0.1% to about 10%, more preferably from about 1%> to about 5%, of the composition.
- Exemplary chelators that are useful herem are disclosed m International Publication No 91/16035, Bush et al., published 10/31/95, and International Publication No 91/16034, Bush et al , published 10/31/95.
- compositions of the present mvention may optionally compnse a flavonoid compound
- Flavonoids are broadly disclosed m U S Patents 5,686,082 and 5,686,367, both of which are herem incorporated by reference
- Flavonoids suitable for use m the present mvention are flavanones selected from the group consistmg of unsubstituted flavanones, mono-substituted flavanones, and mixtures thereof; chalcones selected from the group consistmg of unsubstituted chalcones, mono-substituted chalcones, di- substituted chalcones, tn-substituted chalcones, and mixtures thereof; flavones selected from the group consistmg of unsubstituted flavones, mono-substituted flavones, di-substituted flavones, and mixtures thereof; one or more isoflavones; coumanns selected from the group consistm
- substituted means flavonoids wherem one or more hydrogen atom of the flavonoid has been mdependently replaced with hydroxyl, C1-C8 alkyl, C1-C4 alkoxyl, O-glycoside, and the like or a mixture of these substituents.
- suitable flavonoids include, but are not limited to, unsubstituted flavonone, mono- hydroxy flavanones (e.g., 2'-hydroxy flavanone, 6-hydroxy flavanone, 7-hydroxy flavanone, etc.), mono- alkoxy flavanones (e.g., 5-methoxy flavanone, 6-methoxy flavanone, 7-methoxy flavanone, 4'-methoxy flavanone, etc ), unsubstituted chalcone (especially unsubstituted trans-chalcone), mono-hydroxy chalcones (e g , 2'-hydroxy chalcone, 4'-hydroxy chalcone, etc ), di-hydroxy chalcones (e g , 2',4-dihydroxy chalcone, 2',4'-d ⁇ hydroxy chalcone, 2,2 '-dihydroxy chalcone, 2',3-d ⁇ hydroxy chalcone, 2 ',5 '-dihydroxy
- Prefe ⁇ ed for use herem are uiisubstituted flavanone, methoxy flavanones, unsubstituted chalcone, 2',4-dihydroxy chalcone, and mixtures thereof Most prefe ⁇ ed are unsubstituted flavanone, unsubstituted chalcone (especially the trans isomer), and mixtures thereof
- Flavonoid compounds useful herem are commercially available from a number of sources, e g , Indofine Chemical Company, Inc (Somerville, New Jersey), Steraloids, Inc (Wilton, New Hampshire), and Aldnch Chemical Company, Inc (Milwaukee, Wisconsin)
- the herem descnbed flavonoid compounds are preferably present m the mstant mvention at concentrations of from about 0 01% to about 20%, more preferably from about 0 1% to about 10% and most preferably from about 0 5% to about 5%
- a safe and effective amount of an anti-mflammatory agent may be added to the compositions of the present mvention, preferably from about 0 1% to about 10%, more preferably from about 0 5% to about 5%, of the composition
- the anti-inflammatory agent enhances the skm appearance benefits of the present mvention, e g , such agents contnbute to a more uniform and acceptable skm tone or color
- the exact amount of anti-mflammatory agent to be used m the compositions will depend on the particular anti- lnflammatory agent utilized smce such agents vary widely m potency
- Steroidal anfr-niflamrnatory agents mcludmg but not limited to, corticosteroids such as hydrocortisone, hydroxyltnamcmolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desomde, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlonsone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosmolone acetomde, fluocinonide, flucorhne butylesters, fluocortolone, fluprednidene (fluprednyhdene) acetate, flurandrenolone, halcmomde, hydrocortisone acetate,
- the vanety of compounds encompassed by this group are well- known to those skilled m the art
- non-steroidal anti-mflammatory agents one may refer to standard texts, mcludmg Anti-mflammatory and Anti-Rheumatic Drugs, K D Rainsford, Vol I-III, CRC Press, Boca Raton, (1985), and Anti- iriflamrnatory Agents, Chemistry and Pharmacology, 1, R A Sche ⁇ er, et al , Academic Press, New York (1974)
- composition mvention examples include, but are not limited to
- oxicams such as pnoxicam, lsoxicam, tenoxicam, sudoxicam, and CP-14,304,
- sahcylates such as aspirin, disalcid, benorylate, tnhsate, safapryn, solpnn, diflunisal, and fendosal
- the acetic acid denvatives such as diclofenac, fenclofenac, lndomethacm, sulmdac, tolmetm, isoxepac, furofenac, tiopmac, zidometacm, acematacin, fentiazac, zomepnac, clmdanac, oxepmac, felbmac, and ketorolac,
- the fenamates such as mefenamic, meclofenamic, flufenamic, mflumic, and tolfenamic acids
- the propiomc acid denvatives such as lbuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pirprofen, carprofen, oxaprozm, pranoprofen, miroprofen, tioxaprofen, suprofen, almmoprofen, and tiaprofenic, and
- the pyrazoles such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and tnmethazone
- non-steroidal ann-inflammatory agents may also be employed, as well as the dermatologically acceptable salts and esters of these agents
- etofenamate a flufenamic acid denvative
- lbuprofen, naproxen, flufenamic acid, etofenamate, aspinn, mefenamic acid, meclofenamic acid, pnoxicam and felbmac are prefe ⁇ ed
- lbuprofen, naproxen, ketoprofen, etofenamate, aspirin and flufenamic acid are most preferred
- Such agents may suitably be obtained as an extract by suitable physical and/or chemical isolation from natural sources (e g , plants, fungi, by-products of microorganisms)
- natural sources e g , plants, fungi, by-products of microorganisms
- candehlla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants m the genus Rubia, particularly Rubia Cordifolia), and Guggal (extracted from plants m the genus Commiphora, particularly Commiphora Mukul), kola extract, chamomile, and sea whip extract may be used
- Additional anti-mflammatory agents useful herem include compounds of the Liconce (the plant genus/species Glycy ⁇ hiza glabra) family, mcludmg glycy ⁇ hetic acid, glycyrrhrzic acid, and denvatives thereof (e g , salts and esters)
- Suitable salts of the foregomg compounds mclude metal and ammomum salts
- Suitable esters mclude C2 - C24 saturated or unsaturated esters of the acids, preferably CIO - C24, more preferably C16 - C24
- Specific examples of the foregomg m clude oil soluble liconce extract, the glycynhizic and glycy ⁇ hetic acids themselves, monoammonium glycy ⁇ hizinate, monopotassium glycyrthizinate, dipotassium glycy ⁇ hizinate, 1-beta-glycynhet ⁇
- compositions of the present mvention may also compnse a safe and effective amount of an anti-celluhte agent Suitable agents may mclude, but are not limited to, xanfhine compounds (e g , caffeme, theophylhne, fheobromine, and aminophylhne)
- xanfhine compounds e g , caffeme, theophylhne, fheobromine, and aminophylhne
- compositions of the present mvention may also comprise a safe and effective amount of a topical anesthetic
- topical anesthetic drugs mclude benzocaine, hdocaine, bupivacame, chlorprocame, dibucame, etidocame, mepivacame, tetracaine, dyclonine, hexylcame, procaine, ***e, ketamine, pramoxme, phenol, and pharmaceutically acceptable salts thereof
- compositions of the present mvention may compnse a tanning active When present, it is preferable that the compositions compnse from about 0 1% to about 20%, more preferably from about 2% to about 7%, and most preferably from about 3% to about 6%, by weight of the composition, of dihydroxyacetone as an artificial tanning active
- Dihydroxyacetone which is also known as DHA or l,3-d ⁇ hydroxy-2-propanone, is a white to off- white, crystalline powder
- This matenal can be represented by the chemical formula C3H603 and the following chemical structure
- the compound can exist as a mixture of monomers and dimers, with the dimers predominating m the solid crystalline state Upon heatmg or melting, the dimers break down to yield the monomers This conversion of the dimenc form to the monomenc form also occurs in aqueous solution Dihydroxyacetone is also known to be more stable at acidic pH values See The Merck Index, Tenth Edition, entry 3167, p 463 (1983), and "Dihydroxyacetone for Cosmetics", E Merck Technical Bulletin, 03-304 110, 319 897, 180 588.
- compositions of the present mvention may compnse an additional skm lightemng agent
- the compositions preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2%, by weight of the composition, of a skm lightemng agent.
- Suitable skm lightemng agents mclude those known m the art, mcludmg kojic acid, arbutm, macmaimde, ascorbic acid and denvatives thereof, e g , magnesium ascorbyl phosphate or sodium ascorbyl phosphate.
- Skm lightemng agents suitable for use herein also mclude those descnbed m copendmg patent application Senal No 08/479,935, filed on June 7, 1995 in the name of Hillebrand, co ⁇ espondmg to PCT Application No U.S 95/07432, filed 6/12/95; and copendmg patent application Senal No. 08/390,152, filed on February 24, 1995 m the names of Kalla L Kvalnes, Mitchell A DeLong, Barton J Bradbury, Curtis B. Motley, and John D Carter, co ⁇ espondmg to PCT Application No U.S 95/02809, filed 3/1/95, published 9/8/95
- compositions of the present mvention may compnse an antimicrobial or antifungal active
- actives are capable of destroying microbes, preventmg the development of microbes or preventing the pathogenic action of microbes.
- a safe and effective amount of an antimicrobial or antifungal active may be added to the present compositions, preferably, from about 0 001% to about 10%, more preferably from about 0.01%) to about 5%>, and most preferably from about 0 05% to about 2%>.
- antimicrobial and antifungal actives examples include ⁇ -lactam drugs, qumolone drugs, ciprofloxacin, norfloxacin, tetracychne, eryfhromycm, amikacm, 2,4,4'-tnchloro-2'-hydroxy diphenyl ether, 3,4,4'-t ⁇ chlorobaml ⁇ de, phenoxyethanol, phenoxy propanol, phenoxyisopropanol, doxycychne, capreomycm, chlorhexidine, chlortetracychne, oxytetracychne, clmdamycm, ethambutol, hexamidine lsethionate, metronidazole, pentamidine, gentamicin, kanamycin, lmeomycm, methacychne, methenamine, minocychne, neomycin, netilmicin, paromomycm, str
- actives useful herem include those selected from the group consistmg of salicylic acid, benzoyl peroxide, 3-hydroxy benzoic acid, glycohc acid, lactic acid, 4-hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutano ⁇ c acid, 2-hydroxypentano ⁇ c acid, 2-hydroxyhexanoic acid, cis-retmoic acid, trans-retmoic acid, retmol, phytic acid, N-acetyl-L-cysteme, hpoic acid, azelaic acid, arachidonic acid, benzoylperoxide, tetracyclme, lbuprofen, naproxen, hydrocortisone, acetommophen, resorcmol, phenoxyefhanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-tnchloro-2'-hydroxy diphenyl ether, 3,4,4'-
- compositions of the subject mvention may optionally contam a sunscreen active
- sunscreen active mcludes both sunscreen agents and physical sunblocks. Suitable sunscreen actives may be orgamc or morgamc.
- sunscreen actives are suitable for use herem.
- Sagarin, et al at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology (1972), discloses numerous suitable actives
- Specific suitable sunscreen actives mclude, for example p-aminobenzoic acid, its salts and its denvatives (ethyl, isobutyl, glyceryl esters, p-dunethylammobenzoic acid), anthranilates (i.e., o-amino- benzoates, methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters), sahcylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-pro-pyleneglycol esters); cinnamic acid denv
- 2-ethylhexyl-p-methoxycinnamate commercially available as PARSOL MCX
- 4,4'-t- butyl methoxydibenzoyl-methane commercially available as PARSOL 1789
- 2-hydroxy-4- methoxybenzophenone 2-hydroxy-4- methoxybenzophenone, octyldunethyl-p-a ⁇ unobenzoic acid, digalloylt ⁇ oleate, 2,2-d ⁇ hydroxy-4- methoxybenzophenone, ethyl-4-(b ⁇ s(hydroxy-propyl))ammobenzoate
- 2-ethylhexyl-2-cyano-3,3- diphenylacrylate 2-ethylhexyl-sahcylate
- glyceryl-p-ammobenzoate 3,3,5-tn-methylcyclohexylsal ⁇ cylate, mefhylanthranilate
- compositions useful m the subject mvention are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoyl-mefhane, 2-hydroxy-4-methoxybenzo- phenone, 2-phenylbenz ⁇ m ⁇ dazole-5-sulfon ⁇ c acid, octyldimethyl-p-ammobenzoic acid, octocrylene and mixtures thereof.
- compositions are sunscreen actives such as those disclosed m U.S Patent No 4,937,370 issued to Sabatelh on June 26, 1990, and U S Patent No 4,999,186 issued to Sabatelh & Spirnak on March 12, 1991
- the sunscreening agents disclosed therein have, m a smgle molecule, two distmct chromophore moieties which exhibit different ultra-violet radiation absorption spectra
- One of the chromophore moieties absorbs predominantly m the UVB radiation range and the other absorbs strongly m the UVA radiation range.
- Prefened members of this class of sunscreening agents are 4-N,N-(2-ethylhexyl)methyl- aminobenzoic acid ester of 2,4-d ⁇ hydroxybenzophenone, N,N-d ⁇ -(2-ethylhexyl)-4-am ⁇ nobenzo ⁇ c acid ester with 4-hydroxyd ⁇ benzoylmefhane; 4-N,N-(2-ethylhexyl)methyl-am ⁇ nobenzo ⁇ c acid ester with 4- hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl)mefhyl-ammobenzoic acid ester of 2-hydroxy-4-(2- hydroxyethoxy)benzophenone; 4-N,N-(2-ethylhexyl)-mefhylammobenzo ⁇ c acid ester of 4-(2- hydroxyethoxy)d ⁇ benzoylmethane, N,N-d ⁇ -(2-ethylhexyl
- sunscreen actives include 4,4'-t-butylmethoxyd ⁇ benzoylmefhane, 2-ethylhexyl- p-methoxycinnamate, phenyl benzunidazole sulfomc acid, zmc oxide, titanium dioxide, octocrylene, and combinations thereof
- a safe and effective amount of the sunscreen active is used, typically from about 1% to about 20%, more typically from about 2%> to about 10% by weight of the composition Exact amounts will vary dependmg upon the sunscreen chosen and the desned Sun Protection Factor (SPF).
- SPF Sun Protection Factor
- compositions of the present mvention may compnse a conditioning agent selected from the group consisting of humectants, moisturizers, or skm conditioners
- a vanety of these matenals can be employed and each can be present at a level of from about 0.01% to about 20%>, more preferably from about
- matenals mclude, but are not limited to, guamdme; urea, glycohc acid and glycolate salts (e.g ammomum and quaternary alkyl ammomum); salicylic acid; lactic acid and lactate salts (e.g , ammomum and quaternary alkyl ammomum); aloe vera m any of its vanety of forms (e.g , aloe vera gel), polyhydroxy alcohols such as sorbitol, glycerol, hexanetnol, butanetnol, propylene glycol, butylene glycol, hexylene glycol and the like, polyethylene glycols; sugars (e.g., mehbiose) and starches; sugar and starch denvatives (e.g , alkoxylated glucose, fucose); hy
- vanous C1-C30 monoesters and polyesters of sugars and related matenals are derived from a sugar or polyol moiety and one or more carboxyhc acid moieties Such ester matenals are further described m, U S Patent No 2,831,854, U S Patent No 4,005,196, to Jandacek, issued January 25, 1977, U S Patent No 4,005,195, to Jandacek, issued January 25, 1977, U S Patent No 5,306,516, to Letton et al, issued Apnl 26, 1994, U S Patent No 5,306,515, to Letton et al, issued Apnl 26, 1994, U S Patent No 5,305,514, to Letton et al, issued Apnl 26, 1994, U S Patent No 4,797,300, to Jandacek et al, issued January 10, 1989, U S Patent No 3,963,699, to Rizzi et al, issued June 15, 1976, U S Patent No 4,518,772, to Volpenhein, issued May 21,
- the conditioning agent is selected from the group consisting of glycerol, urea, guanidine, sucrose polyester, and combmations thereof
- compositions of the present mvention can compnse one or more thickening agents, preferably from about 0 1% to about 5%, more preferably from about 0 1% to about 3%, and most preferably from about 0 25% to about 2%, by weight of the composition
- Nonlimiting classes of thickening agents include those selected from the group consistmg of a) Carboxyhc Acid Polymers
- polymers are crosslinked compounds contammg one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherem the crosslinking agent contams two or more carbon-carbon double bonds and is derived from a polyhydnc alcohol
- Polymers useful m the present invention are more fully descnbed in U S Patent No 5,087,445, to Haffey et al, issued February 11, 1992, U S Patent No 4,509,949, to Huang et al, issued Apnl 5, 1985, U S Patent No 2,798,053, to Brown, issued July 2, 1957, and m CTFA International Cosmetic Ingredient Dictionary, Fourth Edition, 1991, pp 12 and 80
- carboxyhc acid polymers useful herem include the carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytntol
- the carbomers are available as the Carbopol® 900 series from B F Goodnch (e g , Carbopol® 954)
- other suitable carboxyhc acid polymenc agents mclude copolymers of C 10-30 alkyl acrylates with one or more monomers of acrylic acid, methacryhc acid, or one of then short cham (I e , Cl-4 alcohol) esters, wherem the crosslinking agent is an allyl ether of sucrose or pentaerytntol
- These copolymers are known as acrylates/C 10-30 alkyl acrylate crosspolymers and are commercially available as Carbopol® 1342, Carbopol® 1382, Pemulen TR-1, and Pemulen TR-2, from B F Goodnch In other words, examples of carb
- compositions of the present mvention can optionally comprise crosslinked polyacrylate polymers useful as thickeners or gellmg agents mcludmg both catiomc and nomomc polymers, with the catiomcs bemg generally prefe ⁇ ed
- useful crosslinked nomomc polyacrylate polymers and crosslinked catiomc polyacrylate polymers are those described m U S Patent No 5 100,660, to Hawe et al, issued March 31, 1992, U S Patent No 4,849,484, to Heard, issued July 18, 1989, U S Patent No 4,835,206, to Fanar et al, issued May 30, 1989, U S Patent No 4,628,078 to Glover et al issued December 9, 1986, U S Patent No 4,599,379 to Flesher et al issued July 8, 1986, and EP 228,868, to Fanar et al, published July 15, 1987 c) Polyacrylamide Polymers
- compositions of the present mvention can optionally comprise polyacrylamide polymers, especially nomomc polyacrylamide polymers mcludmg substituted branched or unbranched polymers Most prefe ⁇ ed among these polyacrylamide polymers is the nomomc polymer given the CTFA designation polyacrylamide and isoparaffm and laureth-7, available under the Tradename Sepigel 305 from Seppic Corporation (Farrfield, NJ)
- polyacrylamide polymers useful herein mclude multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids
- Commercially available examples of these multi-block copolymers mclude Hypan SR150H, SS500V, SS500W, SSSA100H, from Lipo Chemicals, Inc , (Patterson, NJ) d) Polysacchandes
- Polysacchandes refer to gellmg agents which contam a backbone of repeatmg sugar (l e , carbohydrate) units
- Nonlimiting examples of polysaccha ⁇ de gellmg agents mclude those selected from the group consistmg of cellulose, carboxymethyl hydroxyefhylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystallme cellulose, sodium cellulose sulfate, and mixtures thereof
- the alkyl substituted celluloses In these polymers, the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxyefhylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C10-C30 straight
- gellmg agent gums include matenals selected from the group consisting of acacia, agar, algm, alginic acid, ammomum algmate, amylopectin, calcium algmate, calcium canageenan, carnitme, ca ⁇ ageenan, dextrin, gelatm, gellan gum, guar gum, guar hy ⁇ roxypropyltrimonium chlonde, hecto ⁇ te, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium algmate, potassium ca ⁇ ageenan, propylene glycol algmate, sclerotium gum, sodium carboyxmethyl dextran, sodium
- compositions of the present mvention include a thickening agent selected from the group consistmg of carboxyhc acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers and mixtures thereof, more preferably selected from the group consistmg of carboxyhc acid polymers, polyacrylamide polymers, and mixtures thereof Preparation of Compositions
- compositions of the present invention are generally prepared by conventional methods such as are known m the art of making topical compositions Such methods typically mvolve mixing of the ingredients m one or more steps to a relatively uniform state, with or without heating, coolmg, application of vacuum, and the like Methods for Lighte ng Keratinous Tissue
- compositions of the present mvention are useful for lightemng keratinous tissue, preferably mammalian, and more preferably human keratmous tissue
- the compositions of the present invention are useful for lightemng human skm, more especially facial and hand skm
- the compositions are especially useful for lightemng hyperpigmented regions of skm
- the methods discussed herem may also be used to lighten keratmous tissues such as han , nails, etc.
- the method of lightemng keratmous tissue mvolves topically applymg to the keratmous tissue in need of treatment a safe and effective amount of a composition compnsmg a safe and effective amount of an oxnne compound and a dermatologically acceptable earner for said oxime compound
- the amount of the composition which is applied, the frequency of application and the period of use will vary widely dependmg upon the level of the oxime compound and/or other components of a given composition and the level of lightemng desned, e g , m light of the level of skm pigmentation present m the subject and the rate of further skin pigmentation
- the composition is chronically applied to mammalian skin, preferably human skm
- chrome topical application is meant substantially contmuous topical application of the composition over an extended penod during the subject's lifetime, preferably for a penod of at least about one week, more preferably for a penod of at least about one month, even more preferably for at least about three months, even more preferably for at least about six months, and still more preferably for at least about one year.
- benefits are obtamable after vanous maximum periods of use (e.g., two, five, ten or twenty years), it is prefe ⁇ ed that chrome application contmue throughout the subject's lifetime.
- applications would be on the order of about once or twice per day over such extended periods, however application rates can vary, e.g., from about once per week up to about three tunes per day or more
- compositions of the present mvention can be employed to provide a keratmous tissue lightemng benefit.
- Quantities of the present compositions which are typically applied per application are from about 0.1 mg/cm2 keratmous tissue to about 10 mg/cm2 keratinous tissue
- a particularly useful application amount is about 2 mg/cm2 keratmous tissue.
- the method of lightemng keratmous tissue, especially skm is preferably practiced by applymg a composition m the form of a skm lotion, cream, gel, cosmetic (such as foundation), or the like which is mtended to be left on the keratmous tissue for some esthetic, prophylactic, therapeutic or other benefit
- a composition m the form of a skm lotion, cream, gel, cosmetic (such as foundation), or the like which is mtended to be left on the keratmous tissue for some esthetic, prophylactic, therapeutic or other benefit
- After applymg the composition to the keratmous tissue it is preferably left on the keratmous tissue for a penod of at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, most preferably for at least several hours, e.g., up to about 12 hours.
- the composition can also be applied to keratinous tissue, e.g., skm, under a patch (occlusive, semi-occlusive, non-occlusive) or be contamed m a patch which is then applied to the keratmous tissue.
- the patch can be left on the keratmous tissue for a bnef penod (e.g., approximately 5 minutes) or for an extended penod (e g., up to overnight).
- a moisturizing lotion is prepared by combining the following components utilizing conventional mixing techniques.
- a lotion suitable for use on skin, hair, nails, etc is prepared by combinmg the following components utilizing conventional mixing techniques.
- a cream suitable for use on skm, han, nails, etc. is prepared by combinmg the followmg components utilizing conventional mixing techniques.
- a gel suitable for use on skm, han, nails, etc is prepared by combinmg the followmg components utilizing conventional mixing techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001518021A JP2003528031A (en) | 1999-08-24 | 2000-07-10 | Method for lightening keratin tissue by topical application of oxime compound-containing composition |
MXPA02002006A MXPA02002006A (en) | 1999-08-24 | 2000-07-10 | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions. |
KR1020027002378A KR20020047129A (en) | 1999-08-24 | 2000-07-10 | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions |
EP00945274A EP1206241A1 (en) | 1999-08-24 | 2000-07-10 | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions |
CA002382022A CA2382022A1 (en) | 1999-08-24 | 2000-07-10 | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15044899P | 1999-08-24 | 1999-08-24 | |
US60/150,448 | 1999-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001013882A1 true WO2001013882A1 (en) | 2001-03-01 |
Family
ID=22534580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/018731 WO2001013882A1 (en) | 1999-08-24 | 2000-07-10 | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1206241A1 (en) |
JP (1) | JP2003528031A (en) |
KR (1) | KR20020047129A (en) |
CN (1) | CN1376049A (en) |
AR (1) | AR024753A1 (en) |
AU (1) | AU771020B2 (en) |
CA (1) | CA2382022A1 (en) |
MX (1) | MXPA02002006A (en) |
WO (1) | WO2001013882A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021967A2 (en) * | 2002-09-05 | 2004-03-18 | Galderma Research & Development, S.N.C. | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
EP1707188A1 (en) * | 2005-04-02 | 2006-10-04 | Wella Aktiengesellschaft | Reductive colouring system for keratin fibres |
EP1707187A1 (en) * | 2005-04-02 | 2006-10-04 | Wella Aktiengesellschaft | Reductive colorant for keratin fibres |
EP1813312A2 (en) * | 2002-09-05 | 2007-08-01 | Galderma Research & Development | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3026135A1 (en) | 2016-05-30 | 2017-12-21 | Symrise Ag | Cosmetic compositions comprising sclareolide |
WO2017207021A1 (en) | 2016-05-30 | 2017-12-07 | Symrise Ag | Medicament comprising ginger root co2 extract |
JP7177706B2 (en) | 2016-06-30 | 2022-11-24 | シムライズ アーゲー | Pharmaceutical and cosmetic compositions containing resorcinol derivatives |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016035A1 (en) * | 1990-04-26 | 1991-10-31 | The Procter & Gamble Company | Chelator compositions comprising alpha-diamine compounds |
WO1991016034A1 (en) * | 1990-04-26 | 1991-10-31 | The Procter & Gamble Company | Chelator compositions comprising oxime compounds |
WO1995027485A1 (en) * | 1994-04-08 | 1995-10-19 | The Procter & Gamble Company | Methods of using iron chelating compounds to reduce free radical damage in mammals |
EP1023894A1 (en) * | 1999-01-27 | 2000-08-02 | L'oreal | Cosmetic composition comprising at least a compound containing a phenyloxime fragment |
WO2000056702A1 (en) * | 1999-03-22 | 2000-09-28 | Pfizer Inc. | Resorcinol derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5485854A (en) * | 1994-04-12 | 1996-01-23 | Smiths Industries Medical Systems, Inc. | Safety blood collection tube holder and assembly therefor |
-
2000
- 2000-07-10 CN CN00813233A patent/CN1376049A/en active Pending
- 2000-07-10 WO PCT/US2000/018731 patent/WO2001013882A1/en not_active Application Discontinuation
- 2000-07-10 KR KR1020027002378A patent/KR20020047129A/en not_active Application Discontinuation
- 2000-07-10 EP EP00945274A patent/EP1206241A1/en not_active Withdrawn
- 2000-07-10 MX MXPA02002006A patent/MXPA02002006A/en unknown
- 2000-07-10 CA CA002382022A patent/CA2382022A1/en not_active Abandoned
- 2000-07-10 JP JP2001518021A patent/JP2003528031A/en active Pending
- 2000-07-14 AR ARP000103632A patent/AR024753A1/en unknown
-
2002
- 2002-02-27 AU AU18847/02A patent/AU771020B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016035A1 (en) * | 1990-04-26 | 1991-10-31 | The Procter & Gamble Company | Chelator compositions comprising alpha-diamine compounds |
WO1991016034A1 (en) * | 1990-04-26 | 1991-10-31 | The Procter & Gamble Company | Chelator compositions comprising oxime compounds |
WO1995027485A1 (en) * | 1994-04-08 | 1995-10-19 | The Procter & Gamble Company | Methods of using iron chelating compounds to reduce free radical damage in mammals |
EP1023894A1 (en) * | 1999-01-27 | 2000-08-02 | L'oreal | Cosmetic composition comprising at least a compound containing a phenyloxime fragment |
WO2000056702A1 (en) * | 1999-03-22 | 2000-09-28 | Pfizer Inc. | Resorcinol derivatives |
Non-Patent Citations (1)
Title |
---|
D. JANG: "Melanogenesis Inhibitor from Paper Mulberry", COSMETIC & TOILETRIES, vol. 112, 1997, pages 59-62, XP000971365 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021967A2 (en) * | 2002-09-05 | 2004-03-18 | Galderma Research & Development, S.N.C. | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
WO2004021967A3 (en) * | 2002-09-05 | 2005-02-17 | Galderma Res & Dev | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
EP1813312A2 (en) * | 2002-09-05 | 2007-08-01 | Galderma Research & Development | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
EP1813312A3 (en) * | 2002-09-05 | 2010-03-24 | Galderma Research & Development | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
EP1707188A1 (en) * | 2005-04-02 | 2006-10-04 | Wella Aktiengesellschaft | Reductive colouring system for keratin fibres |
EP1707187A1 (en) * | 2005-04-02 | 2006-10-04 | Wella Aktiengesellschaft | Reductive colorant for keratin fibres |
WO2006107595A1 (en) * | 2005-04-02 | 2006-10-12 | The Procter & Gamble Company | Reductive colorant for keratin fibres |
WO2006107594A1 (en) * | 2005-04-02 | 2006-10-12 | The Procter & Gamble Company | Reductive colouring system for keratin fibres |
US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
Also Published As
Publication number | Publication date |
---|---|
KR20020047129A (en) | 2002-06-21 |
JP2003528031A (en) | 2003-09-24 |
EP1206241A1 (en) | 2002-05-22 |
MXPA02002006A (en) | 2002-09-18 |
CA2382022A1 (en) | 2001-03-01 |
AR024753A1 (en) | 2002-10-23 |
CN1376049A (en) | 2002-10-23 |
AU1884702A (en) | 2002-11-07 |
AU771020B2 (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU771934B2 (en) | Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions | |
US6284802B1 (en) | Methods for regulating the condition of mammalian keratinous tissue | |
AU770510B2 (en) | Skin care compositions containing combination of skin care actives | |
US7235249B2 (en) | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions | |
WO2001013882A1 (en) | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions | |
WO2000069407A1 (en) | Methods for upregulating and/or modulating kgf production and increasing receptivity of keratinocytes to kgf | |
WO2000069408A1 (en) | Methods of regulating the condition of mammalian keratinous tissue | |
WO2000069406A1 (en) | Methods of regulating the condition of mammalian keratinous tissue | |
WO2000069409A1 (en) | Methods for upregulating and/or modulating kgf production and increasing receptivity of keratinocytes to kgf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR KR MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2382022 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027002378 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/002006 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000945274 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 00813233X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000945274 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027002378 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027002378 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000945274 Country of ref document: EP |